These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 8212244)

  • 1. Cyclosporine-induced autoimmunity: critical role of autoregulation in the prevention of major histocompatibility class II-dependent autoaggression.
    Hess AD; Fischer AC; Horwitz LR; Laulis MK
    Transplant Proc; 1993 Oct; 25(5):2811-3. PubMed ID: 8212244
    [No Abstract]   [Full Text] [Related]  

  • 2. Cyclosporine-induced syngeneic graft-versus-host disease: recognition of self MHC class II antigens in vivo.
    Hess AD; Horwitz LR; Laulis MK
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1218-21. PubMed ID: 8442094
    [No Abstract]   [Full Text] [Related]  

  • 3. Kinetics of inducer/effector cell generation in the thymus in cyclosporine-induced autoimmunity.
    Wodzig KW; Majoor GD; van Breda Vriesman PJ
    Transplant Proc; 1993 Oct; 25(5):2819-21. PubMed ID: 8212247
    [No Abstract]   [Full Text] [Related]  

  • 4. Immune tolerance to self-major histocompatibility complex class II antigens after bone marrow transplantation: role of regulatory T cells.
    Hess AD; Thoburn CJ
    Biol Blood Marrow Transplant; 2006 May; 12(5):518-29. PubMed ID: 16635787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological mechanisms governing tolerance to self-major histocompatibility complex antigens after bone marrow transplantation.
    Hess AD; Fischer AC; Horwitz LR; Bright EC; Hess JM
    Transplant Proc; 1995 Feb; 27(1):1370-3. PubMed ID: 7878915
    [No Abstract]   [Full Text] [Related]  

  • 6. Functional divergence of antigen-specific T-lymphocyte responses in syngeneic graft-versus-host disease.
    Thoburn CJ; Miura Y; Bright EC; Hess AD
    Biol Blood Marrow Transplant; 2004 Sep; 10(9):591-603. PubMed ID: 15319771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unexpected T-cell diversity in syngeneic graft-versus-host disease revealed by interaction with peptide-loaded soluble MHC class II molecules.
    Hess AD; Thoburn CJ; Chen W; Bright AE
    Transplantation; 2003 Apr; 75(8):1361-7. PubMed ID: 12717231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclosporine preferentially inhibits clonal deletion of CD8-positive T cells with an MHC class II restricted autoreactive T-cell receptor.
    Severino ME; Laulis MK; Horwitz LR; Hess AD
    Transplant Proc; 1993 Feb; 25(1 Pt 1):520-3. PubMed ID: 8438399
    [No Abstract]   [Full Text] [Related]  

  • 9. Antigen-specific T-lymphocyte responses in acute and chronic syngeneic graft-versus-host disease.
    Hess AD; Thoburn CJ; Miura Y; Bright EC
    Transplant Proc; 2005; 37(1):53-6. PubMed ID: 15808545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A two-phase pathogenesis of graft-versus-host disease in mice.
    van Leeuwen L; Guiffre A; Atkinson K; Rainer SP; Sewell WA
    Bone Marrow Transplant; 2002 Jan; 29(2):151-8. PubMed ID: 11850710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune-mediated vasculopathy.
    Chen W; Thoburn CJ; Miura Y; Sommer M; Hruban R; Qian Z; Baldwin W; Hess AD
    Clin Immunol; 2001 Jul; 100(1):57-70. PubMed ID: 11414746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the pathogenic autoreactive T cells in cyclosporine-induced syngeneic graft-versus-host disease.
    Chen W; Thoburn C; Hess AD
    J Immunol; 1998 Dec; 161(12):7040-6. PubMed ID: 9862741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant neoplasms in cyclosporine-induced autoimmunity.
    Wodzig KW; Majoor GD; Tiebosch AT; de Heer E; van Breda Vriesman PJ
    Transplant Proc; 1993 Oct; 25(5):2816-8. PubMed ID: 8212246
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of posttransplant cyclosporine treatment on the development of syngeneic GVHD in recipients of UV-B irradiated bone marrow cells.
    Ohajekwe OA; Hardy MA; Oluwole SF
    Transplant Proc; 1995 Feb; 27(1):1385. PubMed ID: 7878922
    [No Abstract]   [Full Text] [Related]  

  • 15. Autologous graft-versus-host disease: a new frontier in immunotherapy.
    Hess AD; Jones RJ; Morris LE; Noga SJ; Yeager AM; Vogelsang GB; Santos GW
    Bone Marrow Transplant; 1992; 10 Suppl 1():16-21. PubMed ID: 1521086
    [No Abstract]   [Full Text] [Related]  

  • 16. Similarity of scleroderma-like skin lesions in allogeneic and syngeneic bone marrow transplantation models.
    Bos GM; Majoor GD; Slaaf DW; van de Gaar MJ; Weijmer-van Velzen JS; van Breda Vriesman PJ
    Transplant Proc; 1989 Apr; 21(2):3262-3. PubMed ID: 2652812
    [No Abstract]   [Full Text] [Related]  

  • 17. Sirolimus promotes tolerance for donor and recipient antigens after MHC class II disparate bone marrow transplantation in rats.
    Jäger MD; Liu JY; Timrott KF; Popp FC; Stoeltzing O; Lang SA; Piso P; Geissler EK; Schlitt HJ; Dahlke MH
    Exp Hematol; 2007 Jan; 35(1):164-70. PubMed ID: 17198885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
    Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibition of CD4 graft-versus-host activity in IL-2-treated mice.
    Sykes M; Abraham VS; Harty MW; Pearson DA
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1225-6. PubMed ID: 8442096
    [No Abstract]   [Full Text] [Related]  

  • 20. T-cell development and susceptibility to cyclosporine A-induced autoimmunity in MHC-matched bone marrow/thymus chimeras.
    Damoiseaux J; van de Gaar J; van der Heijden H; van Breda Vriesman P
    Transplant Proc; 1999 May; 31(3):1579-80. PubMed ID: 10331009
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.